Literature DB >> 9439653

Refined genetic localization of the Best disease gene in 11q13 and physical mapping of linked markers on radiation hybrids.

C Graff1, A Eriksson, K Forsman, O Sandgren, G Holmgren, C Wadelius.   

Abstract

Best's macular dystrophy, also known as vitelliform macular degeneration type 2 (VMD-2), is an autosomal dominant eye disorder that causes reduced visual acuity. It generally manifests itself in the teenage years. The gene mutated in VMD-2 patients may provide valuable insight into the biological mechanisms of the far more common disorder age-related macular degeneration. The VMD-2 gene has been localized to 11q13 between UGB and Fc epsilon RI. In order to clone the gene positionally, a large Swedish VMD-2 family dating back to the 17th century was studied for recombinations. Since the last study, another 40 microsatellite markers have been analyzed in the family; the closest centromeric flanking marker, D11S4076, revealed two recombinations and the closest telomeric flanking marker, UGB, revealed one recombination. The recombinations have occurred in affected individuals, which eliminates the potential problem of reduced penetrance. The order and physical distance between 22 markers located at proximal 11q13 were analyzed on the G3 Stanford radiation-reduced cell hybrids. The data suggest that the VMD-2 region flanked by the microsatellite markers D11S4076 and UGB is approximately 980 kb.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439653     DOI: 10.1007/s004390050627

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  2 in total

1.  Best's macular dystrophy in Australia: phenotypic profile and identification of novel BEST1 mutations.

Authors:  A C Cohn; C Turnbull; J B Ruddle; R H Guymer; L S Kearns; S Staffieri; H T Daggett; A W Hewitt; D A Mackey
Journal:  Eye (Lond)       Date:  2010-11-26       Impact factor: 3.775

Review 2.  [VMD2 and its role in Best's disease and other retinopathies].

Authors:  H Stöhr; V Milenkowic; B H F Weber
Journal:  Ophthalmologe       Date:  2005-02       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.